#United States #Bridgewater #RVL Pharmaceuticals #Upneeq #Ocular Aesthetics

RVL Pharmaceuticals Reports Significant Growth in Q3 2026

In the latest quarterly results, RVL Pharmaceuticals Inc. showcased remarkable performance in the third quarter of 2026, marking a period of substantial double-digit revenue growth compared to last year. This upward trend was largely attributed to increasing consumer demand for their flagship product, Upneeq®, along with strategic partnerships and an expanded product line.

Upneeq®, known as oxymetazoline hydrochloride ophthalmic solution, 0.1%, is a pioneering prescription eye drop designed to address the issue of low-lying eyelids due to acquired blepharoptosis. This product has become a cornerstone of RVL's rapidly growing omnichannel platform, which has effectively merged clinical innovation with beauty aesthetics.

Key to this growth has been RVL's strategic initiatives aimed at boosting brand visibility and consumer engagement. The company launched its inaugural national celebrity campaign in the second quarter, further accelerating its outreach into the third quarter. This initiative not only broadened the audience for Upneeq® but also fortified the brand's position as a leader at the intersection of clinical efficacy and beauty.

One of the standout moments of the campaign was a high-profile discussion featuring Dr. Elizabeth Hale, a well-respected dermatologist from New York, alongside Jessica Matlin of the Fat Mascara podcast. This event attracted significant media attention and encouraged dialogue about the importance of beauty and connection amongst consumers and practitioners alike. Furthermore, RVL made a splash at New York Fashion Week, where they brought their brand directly to consumers, promoting real-life engagement and excitement.

In addition to Upneeq®, RVL expanded its offerings with the introduction of Upneeq Reveal™ Under Eye Complex. This new skincare product aims to enhance the eye area by addressing common concerns such as dark circles and fine lines. By venturing into consumer skincare, RVL not only diversifies its product range but also captures additional market segments, thereby reinforcing their long-term growth strategy.

Lori Deo, the Chief Executive Officer of RVL Pharmaceuticals, remarked, "Our third quarter marked an important step in our evolution from a prescription brand to establishing a broader presence in ocular aesthetics." She acknowledged the launch's effectiveness in creating new consumer engagements and expanding market reach, contributing to sustainable long-term growth.

Amy Shah, Chief Growth Officer, echoed these sentiments, highlighting the strong market response to their celebrity campaign which has been pivotal in amplifying engagement and earning media coverage. This has been crucial in fostering discussions around low-lying eyelids and showcasing Upneeq® as a viable treatment option for those affected. Shah noted, "The positive reaction reinforces both the relevance of our message and the size of the opportunity ahead."

Upneeq® not only stands as a groundbreaking product at the intersection of aesthetics and eye care, but it also represents a significant market opportunity, with an estimated total addressable market of $2.5 billion. RVL Pharmaceuticals plans to continue its investment in consumer outreach, product innovation, and expanding commercial capabilities to bolster brand awareness and customer retention.

About RVL Pharmaceuticals

RVL Pharmaceuticals operates on a digitally enabled, vertically integrated platform that combines consumer demand generation, healthcare provider engagement, telemedicine, and data insights. Its flagship product, Upneeq®, provides a non-surgical option for adults facing eyelid drooping, enhancing appearance with noticeable results in minutes. With ongoing expansions into additional beauty treatments, RVL remains committed to pushing the boundaries of ocular wellness and aesthetics.

For further information on RVL Pharmaceuticals and their products, please visit www.rvlpharma.com.